Durhalieve

Durhalieve is a topical corticosteroid formulation developed by Echo Therapeutics for the treatment of corticosteroid-responsive dermatoses. The product was a 1% hydrocortisone cream designed using a proprietary transdermal drug delivery technology intended to enhance skin penetration and efficacy. Echo Therapeutics submitted a New Drug Application (NDA) for Durhalieve to the FDA in late 2006. However, following a merger with Sontra Medical in 2007, the company shifted its strategic focus toward its needle-free continuous glucose monitoring (CGM) system (Symphony) and its skin preparation system (Prelude), leading to the discontinuation of the Durhalieve program before it reached the market.

Brand names

Durhalieve

Other names

hydrocortisone 1% topical